Abivax launches a public offering of American Depositary Shares

French biotechnology company Abivax has announced the launch of a public offering of American Depositary Shares (ADS) in the United States, valued at approximately $600 million. Each ADS represents one Abivax ordinary share, traded on the Nasdaq under the symbol "ABVX". The offering is intended to finance the commercialization of obefazimod, its lead drug candidate, in the United States, as well as other clinical research. The final terms of the offering, including the subscription price and the number of ADSs, will be determined through an accelerated book-building process. Finally, trading of the ordinary shares on Euronext will be suspended on July 1, 2026, to coincide with the opening of the Nasdaq.